An Open-label Window of Opportunity Trial to Evaluate the Activity of Durvalumab (MEDI4736) and Tremelimumab With Platinum-based Chemotherapy (Gemcitabine and Cisplatin) in Intrahepatic Cholangiocarcinoma (ICC)
Latest Information Update: 14 May 2024
At a glance
- Drugs Cisplatin (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary) ; Tremelimumab (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 07 May 2024 Status changed from completed to discontinued.
- 03 May 2024 Status changed from active, no longer recruiting to completed.
- 20 Mar 2024 Status changed from recruiting to active, no longer recruiting.